CCM
SGMO

Cadence Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cadence Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-35,820
Closed -$681K – 688
2018
Q1 		$681K Buy
+35,820
New +$766K 0.04% 448
2015
Q3 		– Sell
-49,707
Closed -$551K – 644
2015
Q2 		$551K Sell
49,707
-36,373
-42% -$469K 0.03% 522
2015
Q1 		$1.35M Buy
86,080
+45,500
+112% +$704K 0.08% 314
2014
Q4 		$617K Buy
+40,580
New +$493K 0.04% 480

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cadence Capital Management's SGMO Position: Q2 2018 in Review

Cadence Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 35,820 shares — an estimated $681K sold.

Cadence Capital Management first reported a position in SGMO in Q4 2014 and held it in 4 quarters. The position peaked at $1.35M in Q1 2015. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

  • Cadence Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
  • Cadence Capital Management sold 35,820 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $681K.
  • Cadence Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 4 quarters.
  • Cadence Capital Management's SANGAMO THERAPEUTICS INC position peaked at $1.35M in Q1 2015.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on Cadence Capital Management's 13F filing for Q2 2018, filed 9 Aug 2018.